Targeting the hinge glycine flip and the activation loop: Novel approach to potent p38α inhibitors

Journal of Medicinal Chemistry

Volumn 55, Issue 17, 2012, Pages 7862-7874

  Martz, Kathrin E ^a   Dorn, Angelika ^a   Baur, Benjamin ^a   Schattel, Verena ^a   Goettert, Márcia I ^a   Mayer Wrangowski, Svenja C ^b   Rauh, Daniel ^b   Laufer, Stefan A ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b TU DORTMUND UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOSUBERONE; DIBENZEPINONE; DIBENZOXEPINE; GLYCINE; PROTEIN SERINE THREONINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; DRUG CONFORMATION; DRUG POTENCY; DRUG TARGETING; HYDROPHOBIC INTERACTION CHROMATOGRAPHY; HYDROPHOBICITY; IC 50; MOLECULAR DOCKING; X RAY CRYSTALLOGRAPHY;

CRYSTALLOGRAPHY, X-RAY; GLYCINE; MAGNETIC RESONANCE SPECTROSCOPY; MITOGEN-ACTIVATED PROTEIN KINASE 14; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEIN KINASE INHIBITORS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 84866313160     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm300951u     Document Type: Article

References (50)

1. Dalrymple, S. A. p38 mitogen activated protein kinase as a therapeutic target for Alzheimer's disease J. Mol. Neurosci. 2002, 19, 295-299 (Pubitemid 36051520)
2. den Broeder, A.; van de Putte, L.; Rau, R.; Schattenkirchner, M.; Van Riel, P.; Sander, O.; Binder, C.; Fenner, H.; Bankmann, Y.; Velagapudi, R.; Kempeni, J.; Kupper, H. A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis J. Rheumatol. 2002, 29, 2288-2298 (Pubitemid 35266018)
3. Feldmann, M.; Brennan, F. M.; Maini, R. N. Rheumatoid arthritis Cell 1996, 85, 307-310 (Pubitemid 26160702)
4. Mikuls, T. R.; Moreland, L. W. TNF blockade in the treatment of rheumatoid arthritis: infliximab versus etanercept Expert Opin. Pharmacother. 2001, 2, 75-84 (Pubitemid 32427715)
5. Cohen, S.; Hurd, E.; Cush, J.; Schiff, M.; Weinblatt, M. E.; Moreland, L. W.; Kremer, J.; Bear, M. B.; Rich, W. J.; McCabe, D. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: Results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial Arthritis Rheum. 2002, 46, 614-624 (Pubitemid 34214243)
6. Lee, J. C.; Laydon, J. T.; McDonnell, P. C.; Gallagher, T. F.; Kumar, S.; Green, D.; McNulty, D.; Blumenthal, M. J.; Heys, J. R.; Landvatter, S. W. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis Nature 1994, 372, 739-746
7. Karcher, S. C.; Laufer, S. A. Successful structure-based design of recent p38 MAP kinase inhibitors Curr. Top. Med. Chem. (Sharjah, United Arab Emirates) 2009, 9, 655-676
8. Lee, M. R.; Dominguez, C. MAP kinase p38 inhibitors: Clinical results and an intimate look at their interactions with p38alpha protein Curr. Med. Chem. 2005, 12, 2979-2994 (Pubitemid 41672487)
9. Liu, Y.; Gray, N. S. Rational design of inhibitors that bind to inactive kinase conformations Nat. Chem. Biol. 2006, 2, 358-364 (Pubitemid 43936934)
10. Pettus, L. H.; Wurz, R. P. Small molecule p38 MAP kinase inhibitors for the treatment of inflammatory diseases: novel structures and developments during 2006-2008 Curr. Top. Med. Chem. 2008, 8, 1452-1467
11. Kumar, S.; Jiang, M. S.; Adams, J. L.; Lee, J. C. Pyridinylimidazole compound SB 203580 inhibits the activity but not the activation of p38 mitogen-activated protein kinase Biochem. Biophys. Res. Commun. 1999, 263, 825-831 (Pubitemid 29490712)
12. Kumar, S.; Boehm, J.; Lee, J. C. p38 MAP kinases: Key signalling molecules as therapeutic targets for inflammatory diseases Nat. Rev. Drug Discovery 2003, 2, 717-726 (Pubitemid 37361787)
13. Moran, N. p38 kinase inhibitor approved for idiopathic pulmonary fibrosis Nat. Biotechnol. 2011, 29, 301
14. Xing, L.; Shieh, H. S.; Selness, S. R.; Devraj, R. V.; Walker, J. K.; Devadas, B.; Hope, H. R.; Compton, R. P.; Schindler, J. F.; Hirsch, J. L.; Benson, A. G.; Kurumbail, R. G.; Stegeman, R. A.; Williams, J. M.; Broadus, R. M.; Walden, Z.; Monahan, J. B. Structural bioinformatics-based prediction of exceptional selectivity of p38 MAP kinase inhibitor PH-797804 Biochemistry 2009, 48, 6402-6411
15. Pharmacia & Upjohn Co.LLC. Crystalline forms of 3-[5-chloro-4-[(2,4- difluorobenzyl) oxy]-6-oxopyrimidin-1(6H)-YL]-N-(2-hydroxyethyl)-4- methylbenzamide. International Patent WO2006040649, 2006.
16. Pharmacia Corp. Diaryl substituted pyridinones. U.S. Patent US2006211694, 2006.
17. Pharmacia Corp. Substituted pyrimidinones. U.S. Patent US7795271, 2010.
18. Norman, P. BMS-582949: crystalline form of a p38alpha inhibitor? WO2008079857 Expert Opin. Ther. Pat. 2009, 19, 1165-1168
19. Malley, M. F. (Bristol-Myers Squibb Company, USA) Crystalline forms of an aryl-substituted pyrazoleamide. International Patent WO 2008079857. 2008.
20. Liu, C.; Lin, J.; Wrobleski, S. T.; Lin, S.; Hynes, J.; Wu, H.; Dyckman, A. J.; Li, T.; Wityak, J.; Gillooly, K. M.; Pitt, S.; Shen, D. R.; Zhang, R. F.; McIntyre, K. W.; Salter-Cid, L.; Shuster, D. J.; Zhang, H.; Marathe, P. H.; Doweyko, A. M.; Sack, J. S.; Kiefer, S. E.; Kish, K. F.; Newitt, J. A.; McKinnon, M.; Dodd, J. H.; Barrish, J. C.; Schieven, G. L.; Leftheris, K. Discovery of 4-(5-(cyclopropylcarbamoyl)-2-methylphenylamino)-5-methyl- N -propylpyrrolo[1,2- f ][1,2,4]triazine-6-carboxamide (BMS-582949), a clinical p38α MAP kinase inhibitor for the treatment of inflammatory diseases J. Med. Chem. 2010, 53, 6629-6639
21. Lee, J. C.; Kassis, S.; Kumar, S.; Badger, A.; Adams, J. L. p38 mitogen-activated protein kinase inhibitors - mechanisms and therapeutic potentials Pharmacol. Ther. 1999, 82, 389-397 (Pubitemid 29255932)
22. Fischer, S.; Koeberle, S. C.; Laufer, S. A. p38alpha mitogen-activated protein kinase inhibitors, a patent review Expert Opin. Ther. Pat. 2011, 21, 1843-1866
23. Laufer, S. A.; Ahrens, G. M.; Karcher, S. C.; Hering, J. S.; Niess, R. Design, synthesis, and biological evaluation of phenylamino-substituted 6,11-dihydro-dibenzo[ b, e ]oxepin-11-ones and dibenzo[ a, d ]cycloheptan-5-ones: Novel p38 MAP kinase inhibitors J. Med. Chem. 2006, 49, 7912-7915 (Pubitemid 46033682)
24. Koeberle, S. C.; Romir, J.; Fischer, S.; Koeberle, A.; Schattel, V.; Albrecht, W.; Grutter, C.; Werz, O.; Rauh, D.; Stehle, T.; Laufer, S. A. Skepinone-L is a selective p38 mitogen-activated protein kinase inhibitor Nat. Chem. Biol. 2011, 8, 141-143
25. Murineddu, G.; Ruiu, S.; Loriga, G.; Manca, I.; Lazzari, P.; Reali, R.; Pani, L.; Toma, L.; Pinna, G. A. Tricyclic pyrazoles. 3. Synthesis, biological evaluation, and molecular modeling of analogues of the cannabinoid antagonist 8-chloro-1-(2′,4′-dichlorophenyl)- N -piperidin-1-yl-1,4,5,6- tetrahydrobenzo[6,7]cyclohepta[1,2-c]pyrazole-3-carboxamide J. Med. Chem. 2005, 48, 7351-7362 (Pubitemid 41743649)
26. Engelhardt, E. L.; Zell, H. C.; Saari, W. S.; Christy, M. E.; Colton, C. D.; Stone, C. A.; Stavorski, J. M.; Wenger, H. C.; Ludden, C. T. Structure-activity relationships in the cyproheptadine series J. Med. Chem. 1965, 8, 829-835
27. Kurokawa, M.; Sato, F.; Masuda, Y.; Yoshida, T.; Ochi, Y.; Zushi, K.; Fujiwara, I.; Naruto, S.; Uno, H.; Matsumoto, J. Synthesis and biological activity of 11-[4-(cinnamyl)-1-piperazinyl]- 6,11-dihydrodibenz[ b, e ]oxepin derivatives, potential agents for the treatment of cerebrovascular disorders Chem. Pharm. Bull. (Tokyo) 1991, 39, 2564-2573
28. Schrödinger Suite 2008 Induced Fit Docking protocol. [Glide version 5.0] Schrödinger, LLC, New York, NY, 2005.
29. Jensen, T. A.; Liang, X.; Tanner, D.; Skjaerbaek, N. Rapid and efficient microwave-assisted synthesis of aryl aminobenzophenones using Pd-catalyzed amination J. Org. Chem. 2004, 69, 4936-4947 (Pubitemid 39014048)
30. Goettert, M.; Graeser, R.; Laufer, S. A. Optimization of a nonradioactive immunosorbent assay for p38alpha mitogen-activated protein kinase activity Anal. Biochem. 2010, 406, 233-234
31. Angell, R.; Aston, N. M.; Bamborough, P.; Buckton, J. B.; Cockerill, S.; deBoeck, S. J.; Edwards, C. D.; Holmes, D. S.; Jones, K. L.; Laine, D. I.; Patel, S.; Smee, P. A.; Smith, K. J.; Somers, D. O.; Walker, A. L. Biphenyl amide p38 kinase inhibitors 3: Improvement of cellular and in vivo activity Bioorg. Med. Chem. Lett. 2008, 18, 4428-4432
32. Backes, A. C.; Zech, B.; Felber, B.; Klebl, B.; Mueller, G. Small-molecule inhibitors binding to protein kinases. Part I: exceptions from the traditional pharmacophore approach of type I inhibition Expert Opin. Drug Discovery 2012, 3, 1409-1425
33. Backes, A. C.; Zech, B.; Felber, B.; Klebl, B.; Mueller, G. Small-molecule inhibitors binding to protein kinase. Part II: the novel pharmacophore approach of type II and type III inhibition Expert Opin. Drug Discovery 2008, 3, 1427-1449
34. Cogan, D. A.; Aungst, R.; Breinlinger, E. C.; Fadra, T.; Goldberg, D. R.; Hao, M. H.; Kroe, R.; Moss, N.; Pargellis, C.; Qian, K. C.; Swinamer, A. D. Structure-based design and subsequent optimization of 2-tolyl-(1,2,3-triazol-1- yl-4-carboxamide) inhibitors of p38 MAP kinase Bioorg. Med. Chem. Lett. 2008, 18, 3251-3255 (Pubitemid 351718328)
35. Wrobleski, S. T.; Lin, S.; Hynes, J., Jr.; Wu, H.; Pitt, S.; Shen, D. R.; Zhang, R.; Gillooly, K. M.; Shuster, D. J.; McIntyre, K. W.; Doweyko, A. M.; Kish, K. F.; Tredup, J. A.; Duke, G. J.; Sack, J. S.; McKinnon, M.; Dodd, J.; Barrish, J. C.; Schieven, G. L.; Leftheris, K. Synthesis and SAR of new pyrrolo[2,1-f][1,2,4]triazines as potent p38 alpha MAP kinase inhibitors Bioorg. Med. Chem. Lett. 2008, 18, 2739-2744 (Pubitemid 351503865)
36. www.proqinase.com. 2012.
37. Scios Inc. Indole-type inhibitors of p38 kinase. U.S. Patent US6890938. 2005.
38. Simard, J. R.; Getlik, M.; Grutter, C.; Schneider, R.; Wulfert, S.; Rauh, D. Fluorophore labeling of the glycine-rich loop as a method of identifying inhibitors that bind to active and inactive kinase conformations J. Am. Chem. Soc. 2010, 132, 4152-4160
39. Boehringer Ingelheim Pharma. Methods of treating COPD and pulmonary hypertension. International Patent WO200501862. 2005.
40. Ahn, Y. M.; Clare, M.; Ensinger, C. L.; Hood, M. M.; Lord, J. W.; Lu, W. P.; Miller, D. F.; Patt, W. C.; Smith, B. D.; Vogeti, L.; Kaufman, M. D.; Petillo, P. A.; Wise, S. C.; Abendroth, J.; Chun, L.; Clark, R.; Feese, M.; Kim, H.; Stewart, L.; Flynn, D. L. Switch control pocket inhibitors of p38-MAP kinase. Durable type II inhibitors that do not require binding into the canonical ATP hinge region Bioorg. Med. Chem. Lett. 2010, 20, 5793-5798
41. Getlik, M.; Grutter, C.; Simard, J. R.; Nguyen, H. D.; Robubi, A.; Aust, B.; van Otterlo, W. A.; Rauh, D. Structure-based design, synthesis and biological evaluation of N-pyrazole, N′-thiazole urea inhibitors of MAP kinase p38alpha Eur. J. Med. Chem. 2012, 48, 1-15
42. Simard, J. R.; Getlik, M.; Grutter, C.; Pawar, V.; Wulfert, S.; Rabiller, M.; Rauh, D. Development of a fluorescent-tagged kinase assay system for the detection and characterization of allosteric kinase inhibitors J. Am. Chem. Soc. 2009, 131, 13286-13296
43. Bukhtiyarova, M.; Northrop, K.; Chai, X.; Casper, D.; Karpusas, M.; Springman, E. Improved expression, purification, and crystallization of p38alpha MAP kinase Protein Expression Purif. 2004, 37, 154-161 (Pubitemid 39027255)
44. Kabsch, W. Automatic processing of rotation diffraction data from crystals of initially unknown symmetry and cell constants J. Appl. Crystallogr. 1993, 26, 795-800
45. Read, R. J. Pushing the boundaries of molecular replacement with maximum likelihood Acta Crystallogr., Sect. D: Biol. Crystallogr. 2001, 57, 1373-1382 (Pubitemid 36117185)
46. Brunger, A. T.; Adams, P. D.; Clore, G. M.; DeLano, W. L.; Gros, P.; Grosse-Kunstleve, R. W.; Jiang, J. S.; Kuszewski, J.; Nilges, M.; Pannu, N. S.; Read, R. J.; Rice, L. M.; Simonson, T.; Warren, G. L. Crystallography & NMR system: A new software suite for macromolecular structure determination Acta Crystallogr., Sect. D: Biol. Crystallogr. 1998, 54, 905-921
47. Murshudov, G. N.; Vagin, A. A.; Dodson, E. J. Refinement of macromolecular structures by the maximum-likelihood method Acta Crystallogr., Sect. D: Biol. Crystallogr. 1997, 53, 240-255 (Pubitemid 27235885)
48. Emsley, P.; Cowtan, K. Coot: Model-building tools for molecular graphics Acta Crystallogr., Sect. D: Biol. Crystallogr. 2004, 60, 2126-2132 (Pubitemid 41742764)
49. Schuttelkopf, A. W.; van Aalten, D. M. PRODRG: A tool for high-throughput crystallography of protein-ligand complexes Acta Crystallogr., Sect. D: Biol. Crystallogr. 2004, 60, 1355-1363 (Pubitemid 41079731)
50. Laskowski, R. A.; MacArthur, M. W.; Moss, D. S.; Thornton, J. M. PROCHECK: A program to check the stereochemical quality of protein structures J. Appl. Crystallogr. 1993, 26, 283-291